Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Drugs in R&D

Showing results (1-10 of 1,248) with videos related to

Pageof 125
Sort By:
Drugs in R&D|October 17, 2020
Current PBPK Models: Are They Predicting Tissue Drug Concentration Correctly?Manuel Ibarra, Marta Vázquez, Pietro Fagiolino
Drugs in R&D|October 15, 2020
A Pharmacokinetic Bridging Study to Compare Systemic Exposure to Budesonide between Budesonide Oral Suspension and ENTOCORT EC in Healthy IndividualsIvy H Song, Richard D Finkelman, Lan Lan
Drugs in R&D|June 15, 2021
Effect of Landiolol Hydrochloride on Hemodynamics in a Histamine-Induced Shock ModelMasaharu Hirano, Tatsuaki Okamura, Tetsuji Nagano, et al.
Drugs in R&D|November 30, 2022
Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus ErythematosusNa Zhang, Hong-Xia Zhang, Yu-Wei Li, et al.
Drugs in R&D|October 10, 2021
Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus ErythematosusXuan Zhou, Tsung-I Lee, Min Zhu, et al.
Drugs in R&D|April 12, 2022
Evaluation of the Pharmacokinetics and Safety of AMG 986 Tablet and Capsule Formulations in Healthy Adult Subjects: A Phase I, Open-Label, Randomized StudyAshit Trivedi, Y-H Kiang, Robert E Saw, et al.
Drugs in R&D|April 29, 2022
Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9Theodore J Kottom, Kyle Schaefbauer, Eva M Carmona, et al.
Drugs in R&D|July 19, 2022
Association between Acid-Suppressive Drugs and Clinical Outcomes in Patients with Nonvalvular Atrial FibrillationHideki Arai, Shinichiro Ueda, Kazutaka Uchida, et al.
Drugs in R&D|October 16, 2010
Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in JapanTsuneo Ishiguchi, Shoki Takahashi
Drugs in R&D|October 16, 2010
Ridaforolimus
Pageof 125

Showing results (1-10 of 1,248) with videos related to

Sort By:
Pageof 125
Drugs in R&D|October 17, 2020
Current PBPK Models: Are They Predicting Tissue Drug Concentration Correctly?Manuel Ibarra, Marta Vázquez, Pietro Fagiolino
Drugs in R&D|October 15, 2020
A Pharmacokinetic Bridging Study to Compare Systemic Exposure to Budesonide between Budesonide Oral Suspension and ENTOCORT EC in Healthy IndividualsIvy H Song, Richard D Finkelman, Lan Lan
Drugs in R&D|June 15, 2021
Effect of Landiolol Hydrochloride on Hemodynamics in a Histamine-Induced Shock ModelMasaharu Hirano, Tatsuaki Okamura, Tetsuji Nagano, et al.
Drugs in R&D|November 30, 2022
Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus ErythematosusNa Zhang, Hong-Xia Zhang, Yu-Wei Li, et al.
Drugs in R&D|October 10, 2021
Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus ErythematosusXuan Zhou, Tsung-I Lee, Min Zhu, et al.
Drugs in R&D|April 12, 2022
Evaluation of the Pharmacokinetics and Safety of AMG 986 Tablet and Capsule Formulations in Healthy Adult Subjects: A Phase I, Open-Label, Randomized StudyAshit Trivedi, Y-H Kiang, Robert E Saw, et al.
Drugs in R&D|April 29, 2022
Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9Theodore J Kottom, Kyle Schaefbauer, Eva M Carmona, et al.
Drugs in R&D|July 19, 2022
Association between Acid-Suppressive Drugs and Clinical Outcomes in Patients with Nonvalvular Atrial FibrillationHideki Arai, Shinichiro Ueda, Kazutaka Uchida, et al.
Drugs in R&D|October 16, 2010
Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in JapanTsuneo Ishiguchi, Shoki Takahashi
Drugs in R&D|October 16, 2010
Ridaforolimus
Pageof 125